Purpose: Phytosterols are plant sterols with structural resemblance to cholesterol. United States Food and Drug Administration (FDA) and Health Canada have approved phytosterols as a cholesterol-lowering agent due to their ability to significantly reduce low-density lipoprotein cholesterol (LDL-C) in the range of 7-12%. However, phytosterols (lipophilic) have the potential to impart higher efficacy in the reduction of LDL-C if formulated in a delivery system that increases its bioavailability. In this work, we aim to develop and characterize a liposomal formulation containing phytosterols and tocopherols; the aim is to enhance cholesterol-lowering ability of phytosterols. We also aim to test the efficacy of brassicasterol (phytosterol unique to canola seeds) which has not yet been approved by the FDA. To prevent oxidation of phytosterols during formulation development and storage, tocopherols (vitamin E) are also added as antioxidants.
Methods: Liposomes containing phytosterols and tocopherols were prepared using phosphatidylcholine as the lipid carrier and formulated using three different approaches -i) thin layer hydration homogenization, ii) thin layer hydration ultra-sonication, and iii) Mozafari method. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was developed and validated for quantifying liposomal phytosterols and tocopherols.
Results: Liposomal vesicles prepared via homogenization and ultrasonication methods were significantly lower in size (<200 nm) in comparison to those produced by the Mozafari method (>200 nm). All three methods showed comparable zeta potential values (-9 to -14 mV), which is adequate for the physical stability of the vesicles. A new validated LC-MS/MS method with a total run time of seven minutes was applied to quantify four phytosterols (brassicasterol, campesterol, stigmasterol, and β-sitosterol) and three tocopherols (alpha, gamma, and delta) simultaneously. The run time of seven minutes is the shortest among reported methods to date. The liposomal formulation prepared by all three methods showed entrapment efficiency >89% for both phytosterols and tocopherols.
Conclusion: Liposomes containing phytosterols and tocopherols were successfully developed and characterized with the aim of enhancing the efficacy of phytosterols. In vivo studies will be conducted using hamster animal model to compare the efficacy of liposomal phytosterols to marketed phytosterols containing products.
Can you comment on the adavantages/disadvantages of the three different formulation methods in terms of ease of preparation, equipment etc?